Basic Addyi Information

• INN (International Nonproprietary Name): Flibanserin
• Brand Names Available In Canada (English): Addyi — Canada (marketed for premenopausal women, 100 mg oral tablets, blister packaging)
• ATC Code: G02CX02 (Other Gynecologicals; used for sexual dysfunctions not classified elsewhere)
• Forms & Dosages: Tablet, oral — 100 mg — Sprout Pharmaceuticals — Blister packs (usually 30‑tablet supply per carton)
• Manufacturers In Canada (English): Sprout Pharmaceuticals, Inc. (United States; sole supplier as of 2025)
• Registration Status In Canada (English): Health Canada approved for acquired, generalized HSDD in premenopausal women
• OTC / Rx Classification: Prescription Only (Rx) in jurisdictions where approved
• Standard Dosage: 100 mg orally once daily at bedtime; assess efficacy after 8 weeks and discontinue if no benefit
• Dosage Adjustments: Not approved for children; not recommended in elderly; contraindicated in severe hepatic impairment; insufficient renal data
• Storage: Store at 20–25°C (68–77°F) and protect from moisture and excessive heat
• Absolute Contraindications: Severe hepatic impairment; concomitant use with moderate or strong CYP3A4 inhibitors; known hypersensitivity to flibanserin or excipients
• Common Side Effects: Dizziness, sleepiness (somnolence), nausea, insomnia, dry mouth

Latest Research Highlights

Patients and clinicians want straight answers about whether addyi meaningfully improves desire.

Canadian and international studies from 2022 to 2025 continue to describe flibanserin as offering modest benefit for acquired, generalized HSDD in premenopausal women.

Pivotal randomised trials and post‑marketing cohort analyses reported small but statistically significant increases in sexually satisfying events compared with placebo.

Effect sizes are generally modest and clinical response is limited to a subset of patients rather than universal improvement.

Safety signals emphasise dizziness, somnolence, nausea and rare reports of hypotension and syncope when alcohol or CYP3A4 inhibitors are involved.

Health Canada labelling reflects these safety issues and aligns with the initial FDA approval for this indication in premenopausal women.

Recent literature contrasts oral flibanserin with injectable bremelanotide and non‑pharmacologic psychosocial treatments, noting different mechanisms, dosing and access pathways.

Canadian reviews stress shared decision making and attention to social determinants like rural access and stigma when interpreting efficacy data.

Suggested table: a 2‑row summary comparing primary outcomes from Canadian versus international pooled trials.

Data highlights suggested as callouts include “Number Needed To Treat” and “Common Adverse Events %”, but exact values are not specified in the available sources.

Clinical Effectiveness In Canada

People ask whether addyi works better than counselling or simply waiting longer for change.

Health Canada approves flibanserin for acquired, generalized HSDD in premenopausal women and the product monograph should be checked for full details.

Approved medicines sold in Canada receive a Drug Identification Number (DIN) when marketed; the exact DIN for Addyi is not specified here.

Evidence synthesis shows modest mean benefit at 8 to 24 weeks with a subset of patients achieving clinically meaningful response.

Canadian guidance emphasises reassessing individual benefit after 8 weeks and stopping treatment if no effect is seen.

Provincial formularies vary and many public drug plans do not routinely list Addyi; special authorisation may be required for public coverage.

Private insurance plans sometimes allow prior authorisation for coverage, subject to documentation and prescriber justification.

Clinicians and pharmacists should consult the product monograph, provincial listings and the patient’s insurer before initiating therapy.

Definition list:

• HSDD: Hypoactive Sexual Desire Disorder, acquired and generalized in premenopausal women.
• Responder: A patient meeting a pre‑specified clinical improvement threshold in trials.
• DIN: Drug Identification Number assigned to marketed products in Canada.
• Special Authorisation: Process to request public formulary coverage for non‑listed drugs.

Clinician steps to assess eligibility:

• Confirm diagnosis of acquired, generalized HSDD and exclude relationship or medical causes.
• Review liver history, concurrent medications and alcohol use.
• Discuss expected modest benefit, common side effects and 8‑week efficacy review.

Key data highlight for counselling: recommended dose is 100 mg at bedtime and efficacy should be assessed at 8 weeks.

Indications And Expanded Uses

Patients often ask whether addyi can help after menopause or for trans and non‑binary people.

Flibanserin is approved only for acquired, generalized HSDD in premenopausal women according to Health Canada and regulatory summaries.

Off‑label uses reported in case reports and online forums include peri‑ or postmenopausal women, trans and non‑binary patients, and combinations with hormone therapy, but evidence is limited.

Canadian prescribers should document the rationale and discuss uncertain benefit and risk when considering off‑label use.

Optimise psychosocial contributors and treat relationship or medical causes before pharmacotherapy.

Shared decision making and informed consent are essential for any off‑label trial, with clear documentation in the chart.

Checklist before prescribing:

• Confirm acquired, generalized HSDD diagnosis and exclude treatable medical causes.
• Check baseline liver function when indicated and review all concomitant medications.
• Assess alcohol consumption and counsel on avoidance around dosing.
• Discuss expected timeline and stop rule at 8 weeks if no benefit.

Use bilingual informed consent templates and be aware of Indigenous and rural access inequities when planning treatment.

Composition And Brand Landscape

A common question is whether “addyi” and “flibanserin” are the same thing.

Flibanserin is the INN and the active ingredient in Addyi, the marketed brand in Canada sold as 100 mg oral tablets in blister packs.

As of 2025 there are no authorised generics or major alternate brand formulations in legitimate markets and patents remain in force through May 9, 2028 in primary markets.

Sprout Pharmaceuticals is the listed supplier and original approvals date back to the FDA decision in 2015 and later Health Canada approval.

Pharmacies should avoid purchasing from unverified online suppliers because fraudulent generics are sometimes offered.

Patient counselling in Canada should include bilingual labelling expectations and pharmacist counselling about storage, dosing and safety.

• Authorised Suppliers: Licensed Canadian retail chains and verified mail‑order pharmacies.
• Red Flags For Counterfeits: unusually low prices, overseas warehouse addresses, no prescription verification.

Retail chains vary in stock and special‑order timelines so rural patients should plan ahead for refills and counselling access.

Contraindications And Special Precautions

People worry about liver problems and alcohol when they hear about addyi.

Absolute contraindications include severe hepatic impairment, concomitant use with moderate or strong CYP3A4 inhibitors, and known hypersensitivity to flibanserin or excipients.

Alcohol co‑use is a major safety concern because of the associated risk of severe hypotension and syncope reflected in labelling and counselling advice.

High‑risk groups include those with liver disease, patients taking CYP3A4 inhibitors such as certain azole antifungals or macrolide antibiotics, and people on multiple CNS depressants.

Special attention is required in older adults where the product is not recommended and in Indigenous and rural communities where comorbidities and monitoring access can be limited.

Absolute versus relative contraindications:

• Absolute: Severe hepatic impairment; moderate/strong CYP3A4 inhibitors; hypersensitivity.
• Relative/Caution: Alcohol consumption; combination with CNS depressants; history of hypotension or syncope.

Common CYP3A4 inhibitor classes to review include azole antifungals, certain macrolide antibiotics and some HIV protease inhibitors.

Clinical advice: document alcohol counselling, perform baseline liver assessment when clinically indicated and advise patients about syncope risk with driving or operating machinery.

Dosage Guidelines

Patients ask how and when to take addyi to reduce side effects and get the best chance of benefit.

The recommended dose is 100 mg orally once daily at bedtime.

Bedtime dosing reduces the impact of common adverse effects such as dizziness and somnolence on daytime activities.

If a dose is missed, skip it and resume the next scheduled dose; do not double doses.

Contraindicated in severe hepatic impairment and use with caution when renal data are insufficient.

Elderly and paediatric use are not recommended or established for this product.

Dose management advice:

• Take at least two hours after the last alcoholic drink and avoid alcohol around dosing.
• Do not combine with moderate or strong CYP3A4 inhibitors without specialist advice.
• Review concomitant sedatives when starting and during the first weeks of therapy.

Pharmacists should provide bilingual counselling and consider privacy and literacy when advising patients, particularly in small communities.

Interactions Overview

Many patients ask if their regular medications or a night out drinking make addyi unsafe.

Major interactions include increased flibanserin exposure and hypotension risk when combined with moderate or strong CYP3A4 inhibitors.

Alcohol interaction is a critical counselling point because co‑use can lead to severe hypotension and syncope; patients should avoid alcohol around dosing.

CNS depressants such as benzodiazepines, opioids and some antidepressants can add to sedation and somnolence risk.

Common lifestyle considerations in Canada include social drinking, over‑the‑counter antihistamines that cause drowsiness and medicinal cannabis that may increase sedation.

• Medications To Avoid/Review: Certain azole antifungals, macrolide antibiotics and HIV protease inhibitors (moderate/strong CYP3A4 inhibitors).
• OTC Interactions: First‑generation antihistamines and other sedating agents.

Pharmacy practice tip: reconcile medications at every refill, provide bilingual interaction leaflets and counsel patients who cross the border for filling because labelling and warnings may differ.

Data highlight warning: Alcohol + flibanserin → hypotension/syncope; counsel accordingly.

Cultural Perceptions And Patient Habits

People often search forums to see real‑world experiences with addyi.

Canadian attitudes to sexual health are becoming more open but remain sensitive in rural, remote and some cultural communities.

Online Canadian forums show mixed patient experiences: some report meaningful benefit and improved satisfaction, while others report side effects or minimal effect.

Indigenous and immigrant populations may face added barriers such as privacy concerns in small communities and fewer prescribers comfortable diagnosing HSDD.

Urban centres like Toronto, Vancouver and Montreal generally offer easier access to specialist services and counselling than rural areas.

Typical patient narratives include benefit, disappointment at side effects, and frustration with cost or access.

• Resources: Local sexual health clinics, provincial telehealth services and pharmacist counselling at major chains can help bridge gaps.
• Recommendation: Use culturally sensitive bilingual materials and telehealth follow‑ups to improve access.

Definition: HSDD is a clinical condition of low sexual desire not explained by relationship issues, medication side effects or other medical conditions.

Availability And Pricing Patterns

Patients commonly ask where to buy addyi and whether insurance will cover it.

Addyi is marketed in Canada as flibanserin 100 mg tablets, usually in 30‑tablet blister packs.

Major chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs may stock or special‑order Addyi, while some smaller rural pharmacies may not routinely carry it.

Licensed online Canadian pharmacies can dispense with a prescription where applicable, and patients should always confirm pharmacy licensure.

Some Canadians compare pricing and coverage with the United States where Addyi is also marketed, but cross‑border fills carry labelling and supply‑chain differences.

Provincial formularies rarely list Addyi as a standard benefit so patients commonly pay out‑of‑pocket or seek private insurance prior authorisation.

In our online pharmacy, addyi is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

Clinicians should discuss cost, alternatives and patient assistance programmes where available to reduce inequity in access.

Comparable Medicines And Preferences

People ask whether there is a “female Viagra” that works like the male drugs.

Addyi remains the only oral, Health Canada‑approved medication specifically for HSDD in premenopausal women.

Alternatives include bremelanotide (Vyleesi), an injectable peptide approved for HSDD in some markets, off‑label testosterone preparations, and compounded products, none of which provide an equivalent oral approved option.

Non‑pharmacologic approaches such as cognitive behavioural therapy, couples therapy and sex therapy are often effective and present fewer systemic risks than medication.

Patient selection factors favouring addyi include being premenopausal, having acquired generalized HSDD, and willingness to avoid alcohol around dosing.

Alternatives are preferred when there are contraindications, desire to avoid daily medication or alcohol use that cannot be changed.

Combining behavioural therapy with pharmacotherapy often yields the best long‑term results and should be considered in shared decision making.

FAQ

Is Addyi covered by public drug plans?

Generally not listed as a routine benefit; special authorisation may be possible depending on the province and the clinical documentation provided.

Can I drink alcohol while taking Addyi?

Counselling warns against alcohol near dosing because of the risk of hypotension and syncope; follow product monograph guidance and speak with your pharmacist.

How soon will I notice a benefit?

Efficacy should be assessed at 8 weeks and treatment discontinued if no meaningful benefit is seen.

Is Addyi safe with my antidepressant?

Interactions vary and CNS depression may be additive; check for CYP3A4 inhibitors and consult your prescriber or pharmacist for a medication review.

Where can I get it in rural Canada?

Local pharmacies can special‑order Addyi and telehealth consults or licensed mail‑order pharmacies are useful options for rural patients.

• When To Call Your Clinician: severe dizziness, fainting, signs of hypersensitivity or unmanageable sedation.
• Bilingual Note: Provide FAQ materials in English and French and ask your pharmacist for counselling at major chains.

Guidelines For Proper Use

What should a pharmacist do before dispensing addyi?

Confirm the diagnosis of acquired, generalized HSDD in a premenopausal woman and review the medical history for liver disease and hypotension.

Reconciling medications to identify CYP3A4 inhibitors and sedating agents is essential prior to supply.

Counsel patients to avoid alcohol around dosing, explain the bedtime regimen of 100 mg once daily and warn about sedation and dizziness.

Document informed consent and provide bilingual counselling materials tailored to the patient’s literacy and privacy needs.

For provincial authorities, include prior‑authorisation guidance, clinical documentation and telepharmacy follow‑up plans for rural care.

Monitoring checklist for the first 8 weeks:

• Baseline assessment: liver history, current meds, alcohol use.
• Week 2–4: check for dizziness, excessive somnolence or intolerable side effects.
• Week 8: formal efficacy review; continue if benefit, otherwise stop.

Pharmacists should advise patients ordering from outside Canada to verify labelling differences and confirm product authenticity when dispensing.

Delivery Across Canada (English)